Is CORT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Cushing's / hypercortisolism growth runway, with revenue (ttm) at ~$831M; Q2 2026 +31.7% YoY. The bear case rests on revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Analysts covering it are spread from $50.00 to $165.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $50.00, -54.6% from the $110.16 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Cushing's / hypercortisolism growth runway. Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The most optimistic analyst target on CORT is $165.00, +49.8% from the $110.16 price. That figure is only reachable if this thesis works close to its best case.

Revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval in Cushing's is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. Valuation is now demanding: after a ~188% gain in 2026 the stock trades near 14x sales and about 25x 2027 consensus EPS, with a trailing P/E above 200x because launch spending depressed recent earnings, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns. The oncology launch is early and unproven at scale, and cash fell from about $515 million in March to about $308 million in June. The most pessimistic published target is $50.00, -54.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Cushing's / hypercortisolism growth runway) stalling in the reported numbers rather than in the narrative, the risk above (revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Its main product is Korlym (mifepristone), a cortisol-blocking drug approved for hypercortisolism in Cushing's syndrome, which drives most of its revenue. In March 2026 the FDA also approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, adding a second commercial product.

Yes, on a full-year basis. It generated roughly $761 million in 2025 revenue and about $54 million of net income over the trailing twelve months to June 2026. It reported a Q1 2026 net loss of about $31 million because of heavy spending to launch Lifyorli, then returned to a ~$42 million profit in Q2. It carries essentially no debt and held about $308 million of cash at the end of June.

Revenue concentration in Korlym combined with generic competition. A court ruling cleared a path for Teva's generic mifepristone, which could erode the franchise that funds most of the company before newer products fully scale.